These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7895165)

  • 41. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers.
    Newcomb JR; Cresswell P
    J Immunol; 1993 Jan; 150(2):499-507. PubMed ID: 8419482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.
    van Luijn MM; van de Loosdrecht AA; Lampen MH; van Veelen PA; Zevenbergen A; Kester MG; de Ru AH; Ossenkoppele GJ; van Hall T; van Ham SM
    PLoS One; 2012; 7(4):e34649. PubMed ID: 22563374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern.
    Xu M; Capraro GA; Daibata M; Reyes VE; Humphreys RE
    Mol Immunol; 1994 Jul; 31(10):723-31. PubMed ID: 8035834
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM.
    Belmares MP; Busch R; Mellins ED; McConnell HM
    Biochemistry; 2003 Jan; 42(3):838-47. PubMed ID: 12534297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins.
    Karp DR; Jenkins RN; Long EO
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9657-61. PubMed ID: 1409679
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural insights into human MHC-II association with invariant chain.
    Wang N; Waghray D; Caveney NA; Jude KM; Garcia KC
    Proc Natl Acad Sci U S A; 2024 May; 121(19):e2403031121. PubMed ID: 38687785
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.
    Zhou Z; Reyes-Vargas E; Escobar H; Rudd B; Rockwood AL; Delgado JC; He X; Jensen PE
    Eur J Immunol; 2016 Apr; 46(4):834-45. PubMed ID: 26707565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DR/CLIP (class II-associated invariant chain peptides) and DR/peptide complexes colocalize in prelysosomes in human B lymphoblastoid cells.
    Stang E; Guerra CB; Amaya M; Paterson Y; Bakke O; Mellins ED
    J Immunol; 1998 May; 160(10):4696-707. PubMed ID: 9590215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Negative regulation by HLA-DO of MHC class II-restricted antigen processing.
    Denzin LK; Sant'Angelo DB; Hammond C; Surman MJ; Cresswell P
    Science; 1997 Oct; 278(5335):106-9. PubMed ID: 9311912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
    Stumptner P; Benaroch P
    EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms.
    Rinderknecht CH; Roh S; Pashine A; Belmares MP; Patil NS; Lu N; Truong P; Hou T; Macaubas C; Yoon T; Wang N; Busch R; Mellins ED
    Immunology; 2010 Sep; 131(1):18-32. PubMed ID: 20408893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules.
    Sievers E; Neumann J; Raftery M; SchOnrich G; Eis-Hübinger AM; Koch N
    Immunology; 2002 Sep; 107(1):129-35. PubMed ID: 12225371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.
    Kropshofer H; Vogt AB; Thery C; Armandola EA; Li BC; Moldenhauer G; Amigorena S; Hämmerling GJ
    EMBO J; 1998 Jun; 17(11):2971-81. PubMed ID: 9606180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
    Thayer WP; Ignatowicz L; Weber DA; Jensen PE
    J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
    van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
    Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
    Bangia N; Watts TH
    Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
    van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
    Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
    J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.